�Palatin Technologies,
Inc. (Amex: PTN) proclaimed the pass completion of a Phase 2a clinical
trial of PL-3994, a novel, long-acting natriuretic peptide sense organ A
(NPRA) agonist under development for treatment of heart failure (HF). The
Phase 2a trial was a randomized, double-blind, placebo-controlled, single
ascension dose study in 21 volunteers with controlled high blood pressure who
received the medication or placebo subcutaneously. The purpose of the study
was to demonstrate that PL-3994 rump be disposed safely to patients pickings
antihypertensive medications commonly administered to spirit failure and
hypertension patients. The evaluations included safety, tolerability,
pharmacokinetics and various pharmacodynamic endpoints, including levels of
cyclic guanosine monophosphate (cGMP), a natural messenger nucleotide.
Dosing concluded with the successful achievement of the primary
endpoint of the survey, a pre-specified reduction in systemic blood
pressure. No volunteer experient a serious or severe adverse event.
Elevations in plasma cGMP levels were all observed for several hours after
single hypodermic doses. Additional data analysis is ongoing and will be
submitted for presentation when the analysis is complete.
"We are excited to confirm that PL-3994 can be given safely to patients
who ar taking rakehell pressure medications," stated Dr. Trevor Hallam,
Palatin's Executive Vice President for Research and Development. "As we
proceed with an extra Phase 2 study later this year, we will focus on
the heart failure patients most in need of new therapies."
The previously announced Phase 1 study demonstrated that PL-3994 privy be
tending safely and leads to a dose-related decrease in blood pressure and
addition in cGMP levels, diuresis (kidney evacuation of h2O) and
natriuresis (kidney excretory product of na). The data from this first study
has been accepted for presentation at the 12th Annual Scientific Meeting of
the Heart Failure Society of America to be held in Toronto, Canada on
September 21-24, 2008.
About Heart Failure (HF) Currently in the U.S., HF affects closely 5 gazillion people with 550,000
new cases of HF diagnosed each year. Despite the intervention of HF with
multiple drugs, nearly all HF patients will experience at least one episode
of acute HF that requires treatment with intravenous medications in the
hospital. There were over 1.1 million hospitalizations for HF in 2004.
Heart failure has tremendous human and financial costs. Estimated organise
costs in the U.S. for HF were $29.6 billion in 2006.
About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical fellowship dedicated to
the development of proprietorship peptide, peptide mimetic and small corpuscle
agonist compounds with a focus on melanocortin and natriuretic peptide
receptor systems. The melanocortin system is involved in a enceinte and
divers number of physiologic functions, and therapeutic agents modulating
this organisation may have the voltage to treat a kind of weather condition and
diseases, including sexual dysfunction, obesity and related disorders,
ischaemia and reperfusion injury, hemorrhagic shock and inflammation-related
diseases. The natriuretic peptide sense organ system has numerous
cardiovascular functions, and therapeutic agents modulating this system may
be useful in treatment of heart failure, hypertension and other
cardiovascular diseases. Palatin's scheme is to develop products and then
form marketing collaborations with industry leaders in ordering to maximise
their commercial potential. The Company currently has collaborations with
AstraZeneca and the Mallinckrodt division of Covidien. For extra
information regarding Palatin, please visit Palatin Technologies' internet site
at hhttp://www.palatin.com
Forward looking Statements Statements near the Company's future expectations, including
statements about its development programs, proposed indications for its
product candidates, pre-clinical activities, clinical activities, marketing
collaborations, and all other statements in this document early than
diachronic facts, ar "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
innovative statements shall be subject to the safe harbors created
thereby. Palatin's actual results may differ materially from those
discussed in the forwards looking statements for diverse reasons,
including, but non limited to the Company's ability to fund development of
its technology, ability to establish and successfully complete clinical
trials and pre-clinical studies and the results of those trials and
studies, dependence on its partners for certain development activities,
need for regulatory approvals and commercial-grade acceptance of its products,
ability to recommence selling and advance commercial banker's acceptance of
NeutroSpec(R), ability to protect its intellectual dimension, and other
factors discussed in the Company's occasional filings with the Securities and
Exchange Commission. The Company is not responsible for for updating for events
that occur after the date of this adjure release.
Palatin Technologies, Inc.
http://www.palatin.com
More info
